selegiline hydrochloride
Drug Details
- Generic Name
- selegiline hydrochloride
- Brand Names
- N/A
- Application Number
- Sponsor
- CATALENT U.K. SWINDON ZYDIS LIMITED
- NDC Codes
- 1
- Dosage Forms
- TABLET, ORALLY DISINTEGRATING
- Routes
- N/A
- Active Ingredients
- SELEGILINE HYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE ZELAPAR is indicated as an adjunct in the management of patients with Parkinson’s disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that ZELAPAR has any beneficial effect in the absence of concurrent levodopa therapy [see Clinical Studies (14 ) ]. ZELAPAR, a monoamine oxidase type B (MAO-B) inhibitor, is indicated as an adjunct in the management of patients with Parkinson’s disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy ( 1 )